Craig J. Thomas
YOU?
Author Swipe
View article: Supplementary Figures S1-10 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Supplementary Figures S1-10 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas Open
Supplemental Figure 1. IRF4-GFP knock-in reporter cell lines. Supplemental Figure 2. IRF4-GFP CRISPR screen in adult T-cell lymphoma and screen controls. Supplemental Figure 3. The OST is essential for DLBCL. Supplemental Figure 4. The rol…
View article: Supplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Supplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas Open
Table S1. Brunello library sgRNA normalized read counts of IRF4 sorted CRISPR screens. Table S2. Segregation score of IRF4 sorted CRISPR screens. Table S3. Glycoproteomics in STT3A or STT3B KO cells. Table S4. Brunello sgRNA Library Normal…
View article: Supplementary Figure S1 from Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication
Supplementary Figure S1 from Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication Open
Figure S1
View article: Supplementary Table S1 from Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication
Supplementary Table S1 from Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication Open
Results of HTS in CCRF-CEM parent and SLFN11-KO cells
View article: Supplementary Table S2 from Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication
Supplementary Table S2 from Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication Open
Results of HTS in K562+Vector and K562+WT SLFN11 cells
View article: Supplementary Figure S3 from Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication
Supplementary Figure S3 from Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication Open
Figure S3
View article: Supplementary Figure S4 from Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication
Supplementary Figure S4 from Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication Open
Figure S4
View article: Supplementary Table S3 from Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication
Supplementary Table S3 from Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication Open
Data for Figure 4B
View article: Supplementary Figure S2 from Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication
Supplementary Figure S2 from Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication Open
Figure S2
View article: Supplemental Figure S4 from Inhibition of NAD<sup>+</sup>-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Supplemental Figure S4 from Inhibition of NAD<sup>+</sup>-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models Open
Supplemental Figure S4: Effect of OT-82 on mechanism of RMS cell death
View article: Supplemental Figure S2 from Inhibition of NAD<sup>+</sup>-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Supplemental Figure S2 from Inhibition of NAD<sup>+</sup>-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models Open
Supplemental Figure S2: Endpoint tumor volumes and mouse weights for in vivo experiments using OT-82 in RMS models
View article: Supplemental Figure S1 from Inhibition of NAD<sup>+</sup>-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Supplemental Figure S1 from Inhibition of NAD<sup>+</sup>-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models Open
Supplemental Figure S1: Effect of NAMPT inhibition and evaluation of NAD+ producing enzymes in a panel of molecularly diverse RMS cell lines and models
View article: Supplemental Methods 1 from Inhibition of NAD<sup>+</sup>-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Supplemental Methods 1 from Inhibition of NAD<sup>+</sup>-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models Open
Supplemental Methods
View article: Supplemental Figure S6 from Inhibition of NAD<sup>+</sup>-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Supplemental Figure S6 from Inhibition of NAD<sup>+</sup>-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models Open
Supplemental Figure S6: Gene set enrichment analysis (GSEA) comparing RMS cell lines that undergo a non-necrotic response to OT-82 versus a necrotic response to OT-82
View article: Supplemental Table S1 from Inhibition of NAD<sup>+</sup>-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Supplemental Table S1 from Inhibition of NAD<sup>+</sup>-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models Open
Supplemental Table S1: Molecular features of RMS cell lines
View article: Supplemental Figure S5 from Inhibition of NAD<sup>+</sup>-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Supplemental Figure S5 from Inhibition of NAD<sup>+</sup>-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models Open
Supplemental Figure S5: Mouse weights during OT-82 retreatment
View article: Supplementary Table 1 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
Supplementary Table 1 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations Open
Unique non-cancer drugs
View article: Supplementary Text from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
Supplementary Text from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations Open
Source data
View article: Supplementary Table 3 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
Supplementary Table 3 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations Open
Unique cell lines
View article: Supplementary Table 5 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
Supplementary Table 5 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations Open
Multivariate prediction
View article: Supplementary Table 2 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
Supplementary Table 2 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations Open
Tissues of origin
View article: An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors
An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors Open
View article: SPPL3-glycosylation axis governs CD22 CAR T-cell susceptibility in B-ALL independent of antigen recognition
SPPL3-glycosylation axis governs CD22 CAR T-cell susceptibility in B-ALL independent of antigen recognition Open
Introduction: CD22-targeted chimeric antigen receptor (CAR) T-cell therapy has shown promising efficacy in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), including in patients who previously failed CD19 CAR T-cell therapy…
View article: Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer Open
View article: Biphasic control of the B cell transcriptome by mTORC1 and GSK3
Biphasic control of the B cell transcriptome by mTORC1 and GSK3 Open
View article: Multiple Epigenetic Mechanisms Functionally Cooperate to Silence Expression of Somatostatin Receptor Type 2 in Pancreatic Neuroendocrine Tumors
Multiple Epigenetic Mechanisms Functionally Cooperate to Silence Expression of Somatostatin Receptor Type 2 in Pancreatic Neuroendocrine Tumors Open
Pancreatic neuroendocrine tumors (PNETs) are a rare and understudied set of cancers, with increasing incidence. Neuroendocrine tumors are unique in the fact that they express high levels of the somatostatin receptor type 2 (SSTR2), which r…
View article: Transcript Identification Using Arrayed Hydrogels With TrapFISH (Adv. Mater. Technol. 18/2025)
Transcript Identification Using Arrayed Hydrogels With TrapFISH (Adv. Mater. Technol. 18/2025) Open
View article: Figure S5 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Figure S5 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models Open
Figure S5 shows that A-1331852, Navitoclax, and S63845 have similar potency across 2D culture and 3D spheroids.
View article: Figure S7 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Figure S7 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models Open
Figure S7 depicts morphological changes of the LuCaP-167CR organoids after treatment with BH3 mimetics as single agents or in combination.
View article: Figure S6 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Figure S6 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models Open
Figure S6 shows the effect of treamtent of 3D spheroids with BH3 mimetics as single agents or in combination.